Home Home Home Inbox Home Search

Event

Fevipiprant, a Potent Selective Prostaglandin D2 Receptor 2 (DP2) Antagonist, Dose-Dependently Inhibits Pulmonary Inflammation in a Mouse Model of Asthma [Board No. P948]

Location: Board no. P948
Session Type: Thematic Poster Session
Sunday
May
20
11:15 AM
1:00 PM

Speaker(s)/Author(s)

David Budd

PhD
Novartis Institutes for Biomedical Research

Veit Johannes. Erpenbeck

MD, PhD
Novartis;Novartis Pharma AG

Olivia Robb

BSc
Pneumolabs Ltd

David Sandham

PhD
Novartis Institutes for Biomedical Research

Hollie Smith

BSc
Pneumolabs Ltd

Gareth Williams

PhD
Novartis Institutes for Biomedical Research

Daniel Wyss

BSc
Novartis Institutes for Biomedical Research

Tadayoshi Mikami

PhD
Novartis Pharma KK

Markus Weiss

PhD
Novartis Pharma AG

Koichiro Asano

MD
Tokai University;Tokai University Sch. of Med.;Tokai University School of Medicine

Ian Knowles

PhD, BSc(Hons)
Pneumolabs Ltd

Lucy Barker

BSc
Novartis Institutes for Biomedical Research

Yoshiki Shiraishi

PhD
Tokai University School of Medicine

Rachael Profit

PhD
Novartis Institutes for Biomedical Research

View Abstract

Fevipiprant, a Potent Selective Prostaglandin D2 Receptor 2 (DP2) Antagonist, Dose-Dependently Inhibits Pulmonary Inflammation in a Mouse Model of Asthma

Parent Sessions

  • A35 - ASTHMA CLINICAL STUDIES II
    05-20-2018 9:15 AM - 4:15 PM
    • Home Home Home Inbox Home Search